Cargando…

Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results

Stereotactic MR-guided Radiotherapy (MRgRT) is an interesting treatment option for adrenal gland metastases (AGM). We reviewed data from 12 consecutive patients treated with MRgRT for an AGM in our center between 14 November 2019 and 17 August 2021. Endpoints were tolerance assessment, the impact of...

Descripción completa

Detalles Bibliográficos
Autores principales: Michalet, Morgan, Bettaïeb, Ons, Khalfi, Samia, Ghorbel, Asma, Valdenaire, Simon, Debuire, Pierre, Aillères, Norbert, Draghici, Roxana, De Méric De Bellefon, Mailys, Charissoux, Marie, Boisselier, Pierre, Demontoy, Sylvain, Marguerit, Alexis, Cabaillé, Morgane, Cantaloube, Marie, Keskes, Aïcha, Bouhafa, Touria, Farcy-Jacquet, Marie-Pierre, Fenoglietto, Pascal, Azria, David, Riou, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821305/
https://www.ncbi.nlm.nih.gov/pubmed/36615093
http://dx.doi.org/10.3390/jcm12010291
_version_ 1784865665274871808
author Michalet, Morgan
Bettaïeb, Ons
Khalfi, Samia
Ghorbel, Asma
Valdenaire, Simon
Debuire, Pierre
Aillères, Norbert
Draghici, Roxana
De Méric De Bellefon, Mailys
Charissoux, Marie
Boisselier, Pierre
Demontoy, Sylvain
Marguerit, Alexis
Cabaillé, Morgane
Cantaloube, Marie
Keskes, Aïcha
Bouhafa, Touria
Farcy-Jacquet, Marie-Pierre
Fenoglietto, Pascal
Azria, David
Riou, Olivier
author_facet Michalet, Morgan
Bettaïeb, Ons
Khalfi, Samia
Ghorbel, Asma
Valdenaire, Simon
Debuire, Pierre
Aillères, Norbert
Draghici, Roxana
De Méric De Bellefon, Mailys
Charissoux, Marie
Boisselier, Pierre
Demontoy, Sylvain
Marguerit, Alexis
Cabaillé, Morgane
Cantaloube, Marie
Keskes, Aïcha
Bouhafa, Touria
Farcy-Jacquet, Marie-Pierre
Fenoglietto, Pascal
Azria, David
Riou, Olivier
author_sort Michalet, Morgan
collection PubMed
description Stereotactic MR-guided Radiotherapy (MRgRT) is an interesting treatment option for adrenal gland metastases (AGM). We reviewed data from 12 consecutive patients treated with MRgRT for an AGM in our center between 14 November 2019 and 17 August 2021. Endpoints were tolerance assessment, the impact of adaptive treatment on target volume coverage and organs at risk (OAR) sparing, local control (LC), and overall survival (OS). The majority of patients were oligometastatic (58.3%), with 6 right AGM, 5 left AGM and 1 left and right AGM. The prescribed dose was 35 to 50 Gy in 3 to 5 fractions. The median PTV V95% on the initial plan was 95.74%. The median V95% of the PTVoptimized (PTVopt) on the initial plan was 95.26%. Thirty-eight (69%) fractions were adapted. The PTV coverage was significantly improved for adapted plans compared to predicted plans (median PTV V95% increased from 89.85% to 91.17%, p = 0.0478). The plan adaptation also significantly reduced Dmax for the stomach and small intestine. The treatment was well tolerated with no grade > 2 toxicities. With a median follow-up of 15.5 months, the 1–year LC and OS rate were 100% and 91.7%. Six patients (50%) presented a metastatic progression, and one patient (8.3%) died of metastatic evolution during the follow-up. Adaptation of the treatment plan improved the overall dosimetric quality of MRI-guided radiotherapy. A longer follow-up is required to assess late toxicities and clinical results.
format Online
Article
Text
id pubmed-9821305
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98213052023-01-07 Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results Michalet, Morgan Bettaïeb, Ons Khalfi, Samia Ghorbel, Asma Valdenaire, Simon Debuire, Pierre Aillères, Norbert Draghici, Roxana De Méric De Bellefon, Mailys Charissoux, Marie Boisselier, Pierre Demontoy, Sylvain Marguerit, Alexis Cabaillé, Morgane Cantaloube, Marie Keskes, Aïcha Bouhafa, Touria Farcy-Jacquet, Marie-Pierre Fenoglietto, Pascal Azria, David Riou, Olivier J Clin Med Article Stereotactic MR-guided Radiotherapy (MRgRT) is an interesting treatment option for adrenal gland metastases (AGM). We reviewed data from 12 consecutive patients treated with MRgRT for an AGM in our center between 14 November 2019 and 17 August 2021. Endpoints were tolerance assessment, the impact of adaptive treatment on target volume coverage and organs at risk (OAR) sparing, local control (LC), and overall survival (OS). The majority of patients were oligometastatic (58.3%), with 6 right AGM, 5 left AGM and 1 left and right AGM. The prescribed dose was 35 to 50 Gy in 3 to 5 fractions. The median PTV V95% on the initial plan was 95.74%. The median V95% of the PTVoptimized (PTVopt) on the initial plan was 95.26%. Thirty-eight (69%) fractions were adapted. The PTV coverage was significantly improved for adapted plans compared to predicted plans (median PTV V95% increased from 89.85% to 91.17%, p = 0.0478). The plan adaptation also significantly reduced Dmax for the stomach and small intestine. The treatment was well tolerated with no grade > 2 toxicities. With a median follow-up of 15.5 months, the 1–year LC and OS rate were 100% and 91.7%. Six patients (50%) presented a metastatic progression, and one patient (8.3%) died of metastatic evolution during the follow-up. Adaptation of the treatment plan improved the overall dosimetric quality of MRI-guided radiotherapy. A longer follow-up is required to assess late toxicities and clinical results. MDPI 2022-12-30 /pmc/articles/PMC9821305/ /pubmed/36615093 http://dx.doi.org/10.3390/jcm12010291 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Michalet, Morgan
Bettaïeb, Ons
Khalfi, Samia
Ghorbel, Asma
Valdenaire, Simon
Debuire, Pierre
Aillères, Norbert
Draghici, Roxana
De Méric De Bellefon, Mailys
Charissoux, Marie
Boisselier, Pierre
Demontoy, Sylvain
Marguerit, Alexis
Cabaillé, Morgane
Cantaloube, Marie
Keskes, Aïcha
Bouhafa, Touria
Farcy-Jacquet, Marie-Pierre
Fenoglietto, Pascal
Azria, David
Riou, Olivier
Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results
title Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results
title_full Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results
title_fullStr Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results
title_full_unstemmed Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results
title_short Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results
title_sort stereotactic mr-guided radiotherapy for adrenal gland metastases: first clinical results
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821305/
https://www.ncbi.nlm.nih.gov/pubmed/36615093
http://dx.doi.org/10.3390/jcm12010291
work_keys_str_mv AT michaletmorgan stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT bettaiebons stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT khalfisamia stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT ghorbelasma stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT valdenairesimon stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT debuirepierre stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT ailleresnorbert stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT draghiciroxana stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT demericdebellefonmailys stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT charissouxmarie stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT boisselierpierre stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT demontoysylvain stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT margueritalexis stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT cabaillemorgane stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT cantaloubemarie stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT keskesaicha stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT bouhafatouria stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT farcyjacquetmariepierre stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT fenogliettopascal stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT azriadavid stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults
AT riouolivier stereotacticmrguidedradiotherapyforadrenalglandmetastasesfirstclinicalresults